Rosai-Dorfman-Destombes disease (RDD) is a rare, benign histiocytic disorder, most often involving lymph nodes but showing ...
Credit: Bristol Myers Squibb. The approval was based on data from the MZL cohort of the open-label, single-arm, phase 2 TRANSCEND FL trial. Breyanzi is prepared from the patient’s T cells, which are ...
Long-term data showed that the addition of Imbruvica did not improve overall survival in patients with marginal zone lymphoma or mantle cell lymphoma. The pharmaceutical companies developing Imbruvica ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback